XRAY — DENTSPLY SIRONA Inc.

Summary of DENTSPLY SIRONA Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Global Sales: $904 million, down 5% year-over-year (8% decline on a constant currency basis). Adjusted for a prior year one-time dealer prebuy, sales were down 2.5%.
• Adjusted EBITDA: 18.4%, an increase of 50 basis points from the previous year, attributed to a favorable product mix and reduced operating expenses.
• Non-GAAP EPS: $0.37, a decline of $0.13 year-over-year, impacted by sales mix, tariffs, and higher tax rates (32% vs. 16% last year).
• Cash from Operations: $79 million; ending cash balance was $363 million.
• Goodwill Impairment: $263 million noncash after-tax charge due to tariffs and lower projected volumes.

2. Strategic Updates and Business Highlights

• Leadership Change: Dan Scavilla has completed his first 90 days as CEO, emphasizing a "Return-to-Growth" action plan with four key pillars: customer focus, U.S. business revitalization, employee empowerment, and operational evolution.
• U.S. Sales Performance: U.S. sales decreased 22.2% year-over-year, with notable declines in Essential Dental Solutions, CAD/CAM, Imaging, and Implants, though Wellspect showed 22.3% growth.
• European Sales: Increased by 9.9% as reported, driven by growth in Connected Technology Solutions and Labs.
• Wellspect Healthcare: Continued strong performance, with a 9.3% increase in sales across regions.

3. Forward Guidance and Outlook

• Revised 2025 Outlook: Expected net sales between $3.6 billion and $3.7 billion, with constant currency sales anticipated to decline by 4% to 5% year-over-year. Adjusted EPS forecasted at approximately $1.60.
• Investment Focus: Plans to increase R&D investments and improve operational efficiencies to support growth in 2026 and beyond.

4. Bad News, Challenges, or Points of Concern

• Sales Decline: Significant drop in U.S. sales, indicating challenges in the market and execution issues, particularly with dealer relationships and competitive positioning.
• Goodwill Impairment: Reflects ongoing challenges with tariffs and lower product volumes, raising concerns about future profitability.
• Leadership Transition: Departure of CFO Matt Garth, which may create temporary instability in financial management and strategy execution.
• Operational Challenges: Need for better alignment and training within sales teams and a more effective approach to customer engagement.

5. Notable Q&A Insights

• U.S. Market Dynamics: CEO Scavilla acknowledged multiple factors contributing to the U.S. sales decline, emphasizing the need for structural improvements and better tools for the sales team.
• Growth Cadence: Scavilla indicated that while he desires immediate growth, a more realistic timeline for stabilization and improvement will be developed over the coming months.
• R&D Investment: Plans to accelerate R&D spending in Q4 to position the company for stronger performance in 2026, with a goal to reach a benchmark of 6-7% of sales over time.
• Distributor Relationships: The company is exploring a multichannel approach, balancing direct sales with dealer partnerships to enhance market presence.
• CFO Search: The new CFO will need to focus on data-driven decision-making and effective communication of financial metrics to support the company's turnaround efforts.

This earnings call reflects a pivotal moment for DENTSPLY SIRONA as it seeks to address significant challenges while laying the groundwork for future growth under new leadership.